Biomea Fusion
BMEA

$8.71

0.23%

Market Cap: $315M

About: Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.

Employees: 112

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,710 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

507% more call options, than puts

Call options by funds: $9.21M | Put options by funds: $1.52M

18% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 28

2% more funds holding

Funds holding: 103 [Q1] → 105 (+2) [Q2]

8% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 26

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

23.41% less ownership

Funds ownership: 88.56% [Q1] → 65.15% (-23.41%) [Q2]

78% less capital invested

Capital invested by funds: $473M [Q1] → $105M (-$367M) [Q2]

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$15

72%

upside

Avg. target

$19.25

121%

upside

High target

$25

187%

upside

4 analyst ratings

4 positive

100%

0 neutral

0%

0 negative

0%

Capital One Naureen Quibria 50% 1-year accuracy 2 / 4 met price target	187%upside $25	Overweight Initiated	29 Aug 2024
Citigroup Yigal Nochomovitz 45% 1-year accuracy 17 / 38 met price target	153%upside $22	Buy Maintained	27 Aug 2024
HC Wainwright & Co. Joseph Pantginis 44% 1-year accuracy 92 / 207 met price target	72%upside $15	Buy Reiterated	1 Aug 2024
HC Wainwright & Co. Joseph Pantginis 44% 1-year accuracy 92 / 207 met price target	72%upside $15	Buy Reiterated	25 Jun 2024

See Analyst Rankings

Financial journalist opinion

Based on 59 articles about BMEA published over the past 30 days

Biomea Fusion, Inc. Being Investigated on Behalf of Biomea Fusion, Inc. Investors. Contact Levi & Korsinsky For Details

NEW YORK, NY / ACCESSWIRE / September 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biomea Fusion, Inc. ("Biomea Fusion, Inc.") (NASDAQ:BMEA) concerning possible violations of federal securities laws. Biomea issued a press release on June 6, 2024, announcing that it "has received notice from the U.S. Food and Drug Administration (FDA) that a full clinical hold has been placed on Biomea's ongoing Phase I/II clinical trials of the Company's investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes (COVALENT-111 and COVALENT-112), respectively.

Biomea Fusion, Inc. Being Investigated on Behalf of Biomea Fusion, Inc. Investors. Contact Levi & Korsinsky For Details

The Schall Law Firm Has Launched An Investigation Into Biomea Fusion, Inc. For Violating Securities Laws And Shareholders Are Urged To Join

LOS ANGELES, CA / ACCESSWIRE / September 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc. ("Biomea" or "the Company") (NASDAQ:BMEA) violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.

The Schall Law Firm Has Launched An Investigation Into Biomea Fusion, Inc. For Violating Securities Laws And Shareholders Are Urged To Join

BMEA ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Biomea Fusion, Inc.

NEW YORK, NY / ACCESSWIRE / September 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biomea Fusion, Inc. ("Biomea Fusion, Inc.") (NASDAQ:BMEA) concerning possible violations of federal securities laws. Biomea issued a press release on June 6, 2024, announcing that it "has received notice from the U.S. Food and Drug Administration (FDA) that a full clinical hold has been placed on Biomea's ongoing Phase I/II clinical trials of the Company's investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes (COVALENT-111 and COVALENT-112), respectively.

BMEA ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Biomea Fusion, Inc.

Biomea Fusion Inc Is Being Looked Into For Securities Fraud And Affected Investors Should Take Part With The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / September 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc. ("Biomea" or "the Company") (NASDAQ:BMEA) violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.

Biomea Fusion Inc Is Being Looked Into For Securities Fraud And Affected Investors Should Take Part With The Schall Law Firm

Levi & Korsinsky Announces an Investigation on Behalf of Biomea Fusion, Inc. (BMEA) Shareholders Who May Have Been Affected by Fraud

NEW YORK, NY / ACCESSWIRE / September 17, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biomea Fusion, Inc. ("Biomea Fusion, Inc.") (NASDAQ:BMEA) concerning possible violations of federal securities laws. Biomea issued a press release on June 6, 2024, announcing that it "has received notice from the U.S. Food and Drug Administration (FDA) that a full clinical hold has been placed on Biomea's ongoing Phase I/II clinical trials of the Company's investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes (COVALENT-111 and COVALENT-112), respectively.

Levi & Korsinsky Announces an Investigation on Behalf of Biomea Fusion, Inc. (BMEA) Shareholders Who May Have Been Affected by Fraud

The Schall Law Firm Is Investigating Whether Biomea Fusion, Inc. Violated Securities Laws And Shareholders Are Invited To Reach Out

LOS ANGELES, CA / ACCESSWIRE / September 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc. ("Biomea" or "the Company") (NASDAQ:BMEA) violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.

The Schall Law Firm Is Investigating Whether Biomea Fusion, Inc. Violated Securities Laws And Shareholders Are Invited To Reach Out

Biomea Fusion, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - BMEA

NEW YORK, NY / ACCESSWIRE / September 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biomea Fusion, Inc. ("Biomea Fusion, Inc.") (NASDAQ:BMEA) concerning possible violations of federal securities laws. Biomea issued a press release on June 6, 2024, announcing that it "has received notice from the U.S. Food and Drug Administration (FDA) that a full clinical hold has been placed on Biomea's ongoing Phase I/II clinical trials of the Company's investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes (COVALENT-111 and COVALENT-112), respectively.

Biomea Fusion, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - BMEA

An Inquiry Has Been Launched Into Biomea Fusion Inc For Possible Securities Fraud And The Schall Law Firm Urges Investor Participation

LOS ANGELES, CA / ACCESSWIRE / September 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc. ("Biomea" or "the Company") (NASDAQ:BMEA) violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.

An Inquiry Has Been Launched Into Biomea Fusion Inc For Possible Securities Fraud And The Schall Law Firm Urges Investor Participation

Biomea Fusion, Inc. (BMEA) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights

NEW YORK, NY / ACCESSWIRE / September 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biomea Fusion, Inc. ("Biomea Fusion, Inc.") (NASDAQ:BMEA) concerning possible violations of federal securities laws. Biomea issued a press release on June 6, 2024, announcing that it "has received notice from the U.S. Food and Drug Administration (FDA) that a full clinical hold has been placed on Biomea's ongoing Phase I/II clinical trials of the Company's investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes (COVALENT-111 and COVALENT-112), respectively.

Biomea Fusion, Inc. (BMEA) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights

The Schall Law Firm Is Looking Into Biomea Fusion, Inc. For Violating Securities Laws And Stakeholders Can Join The Investigation

LOS ANGELES, CA / ACCESSWIRE / September 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc. ("Biomea" or "the Company") (NASDAQ:BMEA) violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.

The Schall Law Firm Is Looking Into Biomea Fusion, Inc. For Violating Securities Laws And Stakeholders Can Join The Investigation

See News Rankings